A Study of Intravenous Mircera in Hemodialysis Patients With Chronic Renal Anemia
Status:
Completed
Trial end date:
2010-06-22
Target enrollment:
Participant gender:
Summary
This single arm study will assess the efficacy, safety and tolerability of once-monthly
administration of intravenous Mircera for the maintenance of hemoglobin levels in
hemodialysis patients with chronic renal anemia. Patients will receive 4-weekly intravenous
injections of Mircera, at a starting dose of 120, 200 or 360 micrograms. The anticipated time
on study treatment is 3-12 months, and the target sample size is 100-500 individuals.